All News

2019

January

Media Release / Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Read More
2018

December

Media Release / Dec 21, 2018

Novartis successfully completes acquisition of Endocyte

Read More
Media Release / Dec 21, 2018

Novartis receives European Commission (EC) approval for expanded indication for Kisqali® (ribociclib)

Read More
Media Release / Dec 20, 2018

Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies

Read More
Media Release / Dec 20, 2018

Novartis announces new CEO of Oncology Business Unit

Read More
President of Advanced Accelerator Applications shares her story for “Women in Science.”
Story / Dec 12, 2018

Women in Science: Susanne Schaffert

Susanne Schaffert, President of Advanced Accelerator Applications, describes her career in science.

Read More
Story / Dec 10, 2018

The changing landscape of cancer treatment

Read More
Media Release / Dec 08, 2018

Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Read More
Media Release / Dec 06, 2018

Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses

Read More
Spatz Caplan and her family
Story / Dec 05, 2018

From patient to patient advocate: how a cancer diagnosis fueled a new career path

Elyse Spatz Caplan’s cancer diagnosis impacted her life in more ways than 1

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More